GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

ABVC Biopharma ABVC · USD

N/A · US listing · 🇺🇸 United States

Compare

0.97

-2.88%

Close of 5 Nov 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$795,950

FY2016FY2025

Net income

−$7.9m

FY2016FY2025

Free cash flow

−$3.0m

FY2016FY2025

Shareholders' equity

$11.1m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$795,950$509,589$152,430$969,783$355,797$483,045$701,719$6,956$3,196$32
Research and development$121,085$179,272$1.1m$2.7m$1.0m$549,658$1.0m$988,721$3.2m$10.0m
Operating income−$7.9m−$4.6m−$6.7m−$15.2m−$11.7m−$8.5m−$3.5m−$6.0m−$4.1m−$11.0m
Net income−$7.9m−$4.9m−$7.8m−$16.4m−$12.8m−$9.8m−$3.6m−$5.6m−$4.2m−$11.0m
Diluted earnings per share-0.34-0.37-1.11-5.11-4.94-4.99-0.19-0.09-3.57-9.40

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$21.1m$7.5m$7.8m$10.9m$13.7m$14.8m$6.9m$96,273$6.6m$18,645
Cash and short-term investments$745,834$928,551$796,092$1.5m$5.9m$5.0m$144,295$40,044$256,925$18,645
Total liabilities$7.8m$6.8m$6.5m$6.3m$4.8m$8.9m$7.1m$5.8m$4.1m$6.5m
Debt$3.5m$3.2m$2.8m$3.4m$3.3m$6.8m$4.6m$800,000$1.2m—
Shareholders' equity$11.1m$1.2m$1.6m$4.5m$8.8m$6.6m−$150,964−$5.7m$1.7m−$6.5m
Shares outstanding23m13m7m3m3m2m19m62m1m1m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$3.0m−$1.8m−$4.2m−$7.4m−$7.6m−$4.6m−$3.1m−$630,195−$1.7m−$3.5m
Capital spending−$5,791−$5−$21,201−$119,692−$17,503−$17,503−$17,503−$17,503——
Free cash flow−$3.0m−$1.8m−$4.2m−$7.5m−$7.6m−$4.6m−$3.2m−$647,698−$1.7m−$3.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——−$795,950$795,950—$1,966$1,966$389,276
Operating income−$768,158−$1.6m−$3.0m−$2.0m−$2.2m−$740,294−$334,158−$311,804
Net income−$736,934−$1.6m−$3.6m−$2.0m−$2.3m−$842,075$229,304−$394,769
Diluted earnings per share-0.03-0.06-0.15-0.09-0.10-0.040.02-0.03
Cash from operations——−$1.0m—————
Total assets$19.4m$19.7m$21.1m$21.2m$16.2m$14.9m$7.5m$14.5m
Cash and short-term investments$94,364$202,509$745,834$257,243$1.1m$824,620—$840,682
Debt$358,107$1.2m$1.9m$1.2m$2.1m$2.8m—$2.6m
Shareholders' equity$10.3m$10.8m$11.1m$12.1m$7.0m$5.4m$1.2m$8.4m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-6.4%10.5%72.8%
Operating income-19.5%-1.4%73.4%
Net income-21.6%-4.2%73.3%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-962.7%-1421.1%-1674.9%-1993.4%
Net margin-981.3%-1525.0%-1826.1%-2113.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-6.3-1.6-1.1-0.7-2.1-1.9-43.3-747.6-18.7-7.1
Price to sales62.215.253.512.175.938.3224.7———

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return321%-59%-70%-64%13%-2%-80%-25%0%146%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 25 Jul 2023
  • 18-to-1 reverse split · 8 May 2019
  • 3.141-for-1 split · 11 Apr 2016
  • 5000-to-1 reverse split · 13 Aug 2015
  • 5-to-1 reverse split · 18 Feb 2011
  • 1.5733-for-1 split · 19 Jun 2007

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.